Hochster Howard S
Department of Medicine, NYU School of Medicine, New York, NY 10016, USA.
Semin Oncol. 2003 Aug;30(4 Suppl 15):62-7. doi: 10.1016/s0093-7754(03)00407-x.
Oxaliplatin is a new third-generation platinum analogue with unique activity in colorectal cancer. This agent has changed the approach to chemotherapy for this disease. Novel biologic or molecular targeting agents are now under study in phase I to III clinical trials. Many of these agents are quite promising in colorectal cancer therapy. Most advanced among these include anti-vascular endothelial growth factor antibodies, antibodies directed against the epidermal growth factor receptor (HER-1), small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor, and the proteasome inhibitor PS-341 (bortezomib). The rationale for combinations with oxaliplatin and early clinical trial results are discussed.
奥沙利铂是一种新型的第三代铂类类似物，在结直肠癌中具有独特的活性。这种药物改变了该疾病的化疗方法。新型生物或分子靶向药物目前正处于I至III期临床试验研究中。其中许多药物在结直肠癌治疗中颇具前景。其中最先进的包括抗血管内皮生长因子抗体、针对表皮生长因子受体（HER-1）的抗体、表皮生长因子受体的小分子酪氨酸激酶抑制剂以及蛋白酶体抑制剂PS-341（硼替佐米）。本文讨论了与奥沙利铂联合使用的理论依据以及早期临床试验结果。
